MannKind Corporation (NASDAQ:MNKD) skyrocketed 18.39%, the stock is rising again seemingly on optimism that the company is targeting a large unmet need in the ever-expanding diabetes space and its main focus is on its wonder-drug: AFREZZA. Some may be hopeful that AFREZZA is going to become the dominant player in the $44B insulin market due to its unique pharmacokinetics/efficacy and convenience. MannKind Corporation (NASDAQ:MNKD) stock opened at $6.05 in last session, and closed at $7.08, while the day range of stock is $6.02 – $7.21. The stock showed a positive weekly performance of 33.33%.
Sangamo BioSciences (NASDAQ:SGMO) had its price target upped by Wedbush to $22.00 in a research note issued to investors on Thursday, AR Network reports. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock opened at $15.70, in last session and closed at $18.88, by gaining 38.32%. The 52 week range of the stock is $6.57 – $19.12. Company’s market capitalization is $1.17 billion.
Sequenom, Inc. (NASDAQ:SQNM) grew 7.32% after declaring that on January 1, 2014, the European Patent Office (EPO) issued patent EP2183693 B1, entitled “Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing,” invented by Drs. Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University of Hong Kong. It has been revealed that the patent claims novel methods for detecting fetal aneuploidy using sequencing and was the first patent filing made in the EPO directed to such novel methods. Sequenom, Inc. (NASDAQ:SQNM) stock decreased 0.00% and finished the last session at $2.64. The EPS of the stock remained -1.05. Company’s market capitalization is $305.49 billion.
Galectin Therapeutics Inc. (NASDAQ:GALT) soared 59.28% yesterday to hit the best since its IPO of $14.20 in sympathy with another company in the same industry, Intercept Pharmaceuticals Inc (NASDAQ:ICPT), which nearly quadrupled after the storming success of its beticholic acid in a trial. The rally comes a day after GALT released a report on the Company’s key scientific, development and regulatory milestones and corporate activity that contributed to the Company’s progress in 2013. Galectin Therapeutics Inc. (NASDAQ:GALT) stock opened the session at $8.75, and closed the session at $13.49. The 52 week range of the stock remained $1.99 – $14.20.